Biomarker evaluation to support clinical translation in schizophrenia

Psychosis represents a group of diseases signified by enormous heterogeneity. As a consequence, diagnosis, prognosis, and treatment decision for individual patients are pretty challenging. Within the project, we shall optimize biomarker signatures of patients with high risk for schizophrenia and with defined psychotic disease. This will be achieved by integration of multimodal patient data and subsequent validation of biomarker signatures with the help of patient-derived neurons.